Profile data is unavailable for this security.
About the company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
- Revenue in USD (TTM)8.12m
- Net income in USD-93.14m
- Incorporated2018
- Employees387.00
- LocationMeiraGTx Holdings PLC450 E 29th St Fl 15NEW YORK 10016-8367United StatesUSA
- Websitehttps://meiragtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chromadex Corp | 91.67m | 1.49m | 496.49m | 106.00 | 343.37 | 14.38 | 213.45 | 5.42 | 0.0189 | 0.0189 | 1.21 | 0.4521 | 1.67 | 3.05 | 23.51 | 864,792.40 | 2.70 | -42.11 | 4.08 | -65.14 | 61.45 | 59.68 | 1.62 | -30.64 | 2.35 | -- | 0.0004 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 519.80m | 116.00 | -- | -- | -- | 20.37 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 530.70m | 180.00 | -- | 2.03 | -- | 3.31 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| OmniAB Inc | 21.71m | -62.38m | 534.10m | 106.00 | -- | 1.82 | -- | 24.60 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| MeiraGTx Holdings PLC | 8.12m | -93.14m | 534.11m | 387.00 | -- | 5.59 | -- | 65.76 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Verve Therapeutics Inc | 24.40m | -197.03m | 534.23m | 255.00 | -- | 1.05 | -- | 21.90 | -2.46 | -2.46 | 0.3033 | 6.01 | 0.0382 | -- | 8.45 | 95,670.59 | -30.87 | -- | -32.86 | -- | -- | -- | -807.62 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Kezar Life Sciences Inc | 7.00m | -98.57m | 537.73m | 58.00 | -- | 0.3565 | -- | 76.82 | -13.55 | -13.55 | 0.962 | 20.67 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Aura Biosciences Inc | 0.00 | -80.69m | 539.71m | 88.00 | -- | 2.82 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Altimmune Inc | 409.00k | -101.35m | 545.82m | 59.00 | -- | 3.58 | -- | 1,334.54 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Q32 Bio Inc | 0.00 | -65.02m | 546.19m | 41.00 | -- | 16.21 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Regenxbio Inc | 84.33m | -238.81m | 552.92m | 344.00 | -- | 1.83 | -- | 6.56 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 560.02m | 150.00 | -- | 2.84 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Alector Inc | 61.51m | -158.41m | 563.11m | 241.00 | -- | 4.73 | -- | 9.16 | -1.71 | -1.71 | 0.6607 | 1.21 | 0.1035 | -- | -- | 252,082.00 | -26.66 | -20.00 | -35.58 | -23.81 | -- | -- | -257.54 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Monte Rosa Therapeutics Inc | 14.98m | -119.39m | 568.31m | 103.00 | -- | 2.77 | -- | 37.95 | -1.83 | -1.83 | 0.2215 | 3.35 | 0.0528 | -- | 33.69 | 112,594.00 | -42.10 | -- | -47.48 | -- | -- | -- | -797.26 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -64.77m | 569.16m | 42.00 | -- | 2.87 | -- | -- | -1.15 | -1.15 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -40.11 | -42.22 | -43.16 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Data as of Nov 08 2024. Currency figures normalised to MeiraGTx Holdings PLC's reporting currency: US Dollar USD
38.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 12 Aug 2024 | 12.53m | 16.19% |
| Adage Capital Management LPas of 30 Jun 2024 | 5.23m | 6.76% |
| Prosight Management LPas of 30 Jun 2024 | 4.35m | 5.62% |
| 683 Capital Management LLCas of 30 Jun 2024 | 2.50m | 3.23% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.23m | 2.88% |
| Royce & Associates LPas of 30 Sep 2024 | 795.39k | 1.03% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 569.48k | 0.74% |
| Geode Capital Management LLCas of 30 Jun 2024 | 495.62k | 0.64% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 400.60k | 0.52% |
| J. Goldman & Co. LPas of 30 Jun 2024 | 389.92k | 0.50% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
